Hepatitis C Virus Co-Infection Increases the Risk of Anti-Tuberculosis Drug-Induced Hepatotoxicity among Patients with Pulmonary Tuberculosis

Lomtadze, Nino; Kupreishvili, Lali; Salakaia, Archil; Vashakidze, Sergo; Sharvadze, Lali; Kempker, Russell R.; Magee, Matthew J.; Rı́o, Carlos del; Blumberg, Henry M.

doi:10.1371/journal.pone.0083892

Cited by 59 publications

(56 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Georgia with high TB-burden HCV infection was much more prevalent among TB patients compared with hepatitis B infection or HIV infection (respectively, 21%, 4.3% and 1.8%) [19]. It is also noteworthy that HCV co-infection was not associated with severe drug-induced hepatotoxicity [19].…”

Section: Discussionmentioning

confidence: 99%

Squamous Cell Lung Cancer in a Male with Pulmonary Tuberculosis

Skowroński¹,

Iwanik

Halicka³

et al. 2015

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Lung cancer and pulmonary tuberculosis (TB) are highly prevalent and representing major public health issues. They share common risk factors and clinical manifestations. It is also suggested that TB predicts raised lung cancer risk likely related to chronic inflammation in the lungs. However, it does not seem to influence the clinical course of lung cancer provided that it is properly treated. We present a case report of a 57-year old male with concurrent TB and lung cancer. He was diagnosed with positive sputum smear for acid fast bacilli (AFB) and subsequent culture of Mycobacterium tuberculosis. Besides, his comorbid conditions were chronic hepatitis C virus (HCV) infection and peripheral artery disease (PAD). Later while on anti-tuberculous treatment (ATT) squamous cell lung cancer (SCC) was confirmed with computed tomography (CT) guided biopsy. Due to poor general condition the patient was not fit for either surgery or radical chemo-and radiotherapy. He was transferred to hospice for palliative therapy. We want to emphasize that both TB and lung cancer should be actively sought for in patients with either disorder. In addition, there is no doubt that these patients with lung cancer and with good response to TB treatment should be promptly considered for appropriate anticancer therapy. Case reportThe interaction between lung cancer and tuberculosis (TB) has been long established [1]. There is good evidence that preexisting TB is independently associated with an increased risk of lung cancer [2]. Besides, solid-organ malignancy raises the likelihood of TB reactivation particularly in patients with old healed TB lesions [3].A 57-year old severe underweight (bodymass-index (BMI) 15 kg/m 2 ) male was admitted to a respiratory ward with a history of 3-week long anorexia, fatigue, purulent cough and 1-month long fever. His cough started 6 months before. He reported significant weight loss of 15 kilos for 6 months. He had no chest pain and haemoptysis. As an out-patient he received the course of amoxicillin with clavulanic acid with short-lived improvement. Also, the patient complained of intermittent claudication after a short walking distance. He was a resident of the shelter for homeless for a few years. His primary profession was a garage worker whereas his most recent occupation was garbage sorting. There was a history of heavy smoking (30-pack years) and alcohol addiction. He had not been drinking for last 2 years. He had no evident contact with a confirmed TB source. In the distant past he underwent an ear-nose-throat operation for the nose deformity. On examination, he was undernourished, nor-

show abstract

Section: Discussionmentioning

confidence: 99%

Squamous Cell Lung Cancer in a Male with Pulmonary Tuberculosis

Skowroński¹,

Iwanik

Halicka³

et al. 2015

Advances in Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…The exact pharmacokinetics of the case and underlying mechanism of drug reaction has not been well characterized. In the case presented here, the patient had recently taken anti‐TB therapy and previous studies suggest that HIV or/and HCV coinfection increases the risk anti‐TB drug‐induced hepatotoxicity . Likewise, another study suggested that 8% patient experience anti‐TB drug‐induced hepatotoxicity .…”

Section: Case Presentationmentioning

confidence: 99%

“…Both TB and HCV are endemic in Southeast Asian countries and Pakistan has the second‐highest prevalence of HCV and fourth‐highest prevalence of multidrug‐resistant TB, worldwide . Some groups are at high risk of acquiring TB than general population such as patients taking immunosuppressive therapy, for example, for chronic kidney disease, diabetes, solid organ transplants, inflammatory bowel disease, and rheumatic or those coinfected with HIV/AIDS or viruses …”

Section: Introductionmentioning

confidence: 99%

Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis

Wahid

2019

Journal of Medical Virology

View full text Add to dashboard Cite

The prevalence of hepatitis C virus/tuberculosis (HCV/TB) coinfection has not been estimated globally but few studies highlight the risk of hepatotoxicity following TB treatment or HCV treatment. Previously reported data highlights the risk of drug‐induced hepatotoxicity associated with three of the first‐line anti‐TB agents: rifampin, isoniazid, and pyrazinamide specifically in patients coinfected with HIV and HCV. Thus far, direct‐acting antiviral (DAA) drug‐induced hepatotoxicity has not been reported in the literature but herein, we observed an unusual case of HCV virological breakthrough and hepatoxicity during treatment with DAA drugs in a patient who has previously been successfully treated for TB.

show abstract

“…Females have an increased risk [14]. In addition, people with hepatitis C virus (HCV) infection have an increased risk [15, 16]. Some compounds in fruits and food supplements can reduce the risk of AT-DILI due to their abilities to inhibit CYP2E1 activity [17] or to increase anti-oxidative activities [18–20].…”

Section: Introductionmentioning

confidence: 99%

Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury

Bao

Rasmussen

et al. 2018

Curr Pharmacol Rep

View full text Add to dashboard Cite

Purpose of this Review In order to combat the development of drug resistance, the clinical treatment of tuberculosis requires the combined use of several anti-tuberculosis (anti-TB) drugs, including isoniazid and rifampicin. Combinational treatment approaches are suggested by the World Health Organization (WHO) and are widely accepted throughout the world. Unfortunately, a major side effect of the treatment is the development of anti-tuberculosis drug-induced liver injury (AT-DILI). Many factors contribute to isoniazid- and rifampicin-mediated AT-DILI and genetic variations are among the most common factors. The purpose of this review is to provide information on genetic variations associated with isoniazid- and rifampicin-mediated AT-DILI. Recent Findings The genetic variations associated with AT-DILI have been identified in the genomic regions within or near genes encoding proteins in the following pathways: drug metabolizing enzymes (NAT2, CYP2E1, and GSTs), accumulation of bile acids, lipids, and heme metabolites (CYP7A1, BSEP, UGTs, and PXR), immune adaptation (HLAs and TNF-α), and oxidant challenge (TXNRD1, SOD1, BACH1, and MAFK). Summary The information summarized in this review considers the genetic bases of risk factors contributing to AT-DILI and provides information that may help for future studies. Some of the implicated genetic variations can be used in the design of genetic tests and serve as biomarkers for the prediction of isoniazid- and rifampicin-mediated AT-DILI risk in personalized medicine.

show abstract

Hepatitis C Virus Co-Infection Increases the Risk of Anti-Tuberculosis Drug-Induced Hepatotoxicity among Patients with Pulmonary Tuberculosis

Cited by 59 publications

References 21 publications

Squamous Cell Lung Cancer in a Male with Pulmonary Tuberculosis

Squamous Cell Lung Cancer in a Male with Pulmonary Tuberculosis

Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis

Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury

Contact Info

Product

Resources

About